We are live on ! Find out more
BBA

Baker Bros. Advisors Portfolio holdings

AUM $17.4B
1-Year Est. Return 131.5%
This Fund
S&P 500
This Quarter Est. Return
+41.99%
1 Year Est. Return
+131.5%
3 Year Est. Return
+336.81%
5 Year Est. Return
+553.16%
10 Year Est. Return
+4,134.93%
AUM
$7.04B
AUM Growth
+$1.98B
Cap. Flow
-$1.2B
Cap. Flow %
-17.09%
Top 10 Hldgs %
79.89%
Holding
87
New
12
Increased
14
Reduced
15
Closed
5

Top Buys

Rank Stock Value
1
GEVA
SYNAGEVA BIOPHARMA CORP COM STK (DE)
GEVA
+$51.7M
2
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$19.5M
3
DSCI
Derma Sciences, Inc. Common Stock (DE)
DSCI
+$16.6M
4
QCOR
QUESTCOR PHARMA INC
QCOR
+$13.7M
5
XOMA
Xoma
XOMA
+$12.5M

Top Sells

Rank Stock Value
1
PCYC
PHARMACYCLICS INC
PCYC
+$195M
2
VPHM
VIROPHARMA INC
VPHM
+$96M
3
CLVS
Clovis Oncology, Inc.
CLVS
+$15.8M
4
AEGR
Aegerion Pharmaceuticals
AEGR
+$8.82M
5
INFI
Infinity Pharmaceuticals, Inc.
INFI
+$8.22M

Sector Composition

Rank Sector Weight
1 Healthcare 42.07%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PCYC
1
DELISTED
PHARMACYCLICS INC
PCYC
$1.25B 17.71%
9,010,211
-1,760,927
-16% -$195M
SGEN
2
DELISTED
Seagen Inc. Common Stock
SGEN
$847M 12.04%
19,322,947
– –
GEVA
3
DELISTED
SYNAGEVA BIOPHARMA CORP COM STK (DE)
GEVA
$651M 9.26%
10,273,182
+1,050,000
+11% +$51.7M
INCY icon
4
Incyte
INCY
$25.3B
$565M 8.03%
14,810,559
– –
ACAD icon
5
Acadia Pharmaceuticals
ACAD
$4.46B
$548M 7.79%
19,955,126
– –
GHDX
6
DELISTED
Genomic Health, Inc.
GHDX
$417M 5.93%
13,650,835
– –
VPHM
7
DELISTED
VIROPHARMA INC
VPHM
$220M 3.12%
5,592,239
-2,936,364
-34% -$96M
XOMA
8
DELISTED
Xoma
XOMA
$103M 1.47%
1,151,619
+137,890
+14% +$12.5M
GILD icon
9
Gilead Sciences
GILD
$166B
$78.3M 1.11%
1,245,800
– –
HALO icon
10
Halozyme
HALO
$9.87B
$77.5M 1.1%
7,017,608
+464,458
+7% +$3.87M
RPRX
11
DELISTED
Repros Therapeutics Inc.
RPRX
$74.5M 1.06%
2,778,654
– –
AEGR
12
DELISTED
Aegerion Pharmaceuticals
AEGR
$70.3M 1%
820,275
-104,068
-11% -$8.82M
CERS icon
13
Cerus
CERS
$577M
$56.8M 0.81%
8,455,306
– –
BMRN icon
14
BioMarin Pharmaceuticals
BMRN
$12B
$56.5M 0.8%
783,311
– –
VNDA icon
15
Vanda Pharmaceuticals
VNDA
$301M
$52.5M 0.75%
4,791,179
+825,000
+21% +$8.81M
BCRX icon
16
BioCryst Pharmaceuticals
BCRX
$2.44B
$48.8M 0.69%
6,699,979
+1,136,364
+20% +$5.76M
STML
17
DELISTED
Stemline Therapeutics, Inc.
STML
$36.3M 0.52%
800,400
-99,600
-11% -$3.25M
DSCI
18
DELISTED
Derma Sciences, Inc. Common Stock (DE)
DSCI
$31.7M 0.45%
2,558,857
+1,200,000
+88% +$16.6M
QCOR
19
DELISTED
QUESTCOR PHARMA INC
QCOR
$31.7M 0.45%
545,846
+230,000
+73% +$13.7M
MRTX
20
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$30M 0.43%
+1,980,074
New +$19.5M
ICPT
21
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
$25M 0.36%
362,847
-100,000
-22% -$4.94M
ARIA
22
DELISTED
Ariad Pharmaceuticals Inc
ARIA
$24.5M 0.35%
1,333,703
-116,297
-8% -$2.26M
MDVN
23
DELISTED
MEDIVATION, INC.
MDVN
$23.9M 0.34%
796,662
– –
PGNX
24
DELISTED
Progenics Pharmaceuticals Inc
PGNX
$21.1M 0.3%
4,200,000
– –
AVNR
25
DELISTED
AVANIR PHARMACEUTICALS, INC CL A
AVNR
$18.7M 0.27%
4,428,591
+850,000
+24% +$4.03M
1
2 3 4

Similar funds

FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
CM
Caption Management Oklahoma City, Oklahoma $17.1B AUM 70.99% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
ASRS
Arizona State Retirement System Phoenix, Arizona $17.1B AUM 30.52% 1-Year Est. Return
PP
Prudential plc London, England, United Kingdom $17.1B AUM 15.7% 1-Year Est. Return
VMPIC
Varma Mutual Pension Insurance Co Helsinki, Finland $17B AUM 24.09% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
BCIM
British Columbia Investment Management Victoria, British Columbia, Canada $17B AUM 31.69% 1-Year Est. Return

Baker Bros. Advisors's Q3 2013 Portfolio in Review

As of Q3 2013, Baker Bros. Advisors held 87 positions worth $7.04B, up 39% from $5.06B the previous quarter. Its ten largest holdings account for 80% of the portfolio.

Baker Bros. Advisors withdrew a net $1.2B in Q3 2013, closing 5 positions and reducing 15 holdings. Its most notable exit was Arqule Inc, an estimated $2.04M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 42% of assets, up from 39% a quarter earlier.

Against the trend, Baker Bros. Advisors opened a new position in Mirati Therapeutics, Inc. Common Stock worth $30M.

  • Baker Bros. Advisors's largest Q3 2013 buy was Mirati Therapeutics, Inc. Common Stock: 1,980,074 shares worth $30M.
  • Baker Bros. Advisors added most to SYNAGEVA BIOPHARMA CORP COM STK (DE) in Q3 2013, an estimated $51.7M increase.
  • Baker Bros. Advisors's biggest Q3 2013 reduction was PHARMACYCLICS INC, cutting an estimated $195M.
  • Baker Bros. Advisors fully exited Arqule Inc in Q3 2013, selling an estimated $2.04M.
  • Baker Bros. Advisors's ten largest holdings make up 80% of its $7.04B portfolio in Q3 2013.
  • Baker Bros. Advisors opened 12 new positions and closed 5 in Q3 2013.
  • Baker Bros. Advisors's portfolio value rose 39% quarter-over-quarter to $7.04B.

Based on Baker Bros. Advisors's 13F filing for Q3 2013, filed 14 Nov 2013.